经颅交流电刺激治疗3型脊髓小脑共济失调：一项随机对照试验。
Transcranial alternating current stimulation for treating spinocerebellar ataxia type 3: A randomized controlled trial.
作者信息
Chen Xinyuan, Liu Xia, Lin Wei, Zhang Lin, Cheng Xiaoping, Huang Ziqiang, Zhang Wanli, Zeng Huating, Lian Yanhua, Zhang Yingjuan, Li Mengcheng, Chen Naping, Huang Shuna, Wang Zhaodi, Wang Xichen, Liu Zhenyi, Yuan Ruying, Chen Xuanyu, Ye Zhixian, Cheng Bi, Zhang Yue, Chen Qunlin, Wang Duolao, Ni Jun, Wang Ning, Fu Ying, Gan Shirui
机构信息
Department of Rehabilitation Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
Department of Rehabilitation Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China; Department of Rehabilitation Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264100, China.
出版信息
Cell Rep Med. 2025 Jun 17;6(6):102162. doi: 10.1016/j.xcrm.2025.102162.
There are no specific treatments for spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disease causing cerebellar dysfunction. Transcranial alternating current stimulation (tACS) can improve cerebellar motor functions, and it has been shown to be safe and effective in treating neurological diseases. This randomized controlled trial (RCT) explored the effects of tACS on SCA3 patients. Participants received either 40-min, 70 Hz, 2 mA tACS or sham stimulation daily for 2 weeks. The primary outcome was met by 80% of the active-tACS group (32/40) and 10% of the sham group (4/40). The active group also showed significantly greater reductions in the Scale for Assessment and Rating of Ataxia (SARA) scores. No serious adverse events occurred, indicating high safety. Therefore, tACS is effective, safe, and feasible for treating SCA3. The study is registered at ClinicalTrials.gov (NCT05557786).
脊髓小脑共济失调3型（SCA3）是一种导致小脑功能障碍的神经退行性疾病，目前尚无特效治疗方法。经颅交流电刺激（tACS）可以改善小脑运动功能，并且已被证明在治疗神经系统疾病方面是安全有效的。这项随机对照试验（RCT）探讨了tACS对SCA3患者的影响。参与者每天接受40分钟、70赫兹、2毫安的tACS或假刺激，持续2周。80%的tACS治疗组（32/40）达到了主要结局，而假刺激组为10%（4/40）。治疗组在共济失调评估与评分量表（SARA）得分上也有显著更大幅度的降低。未发生严重不良事件，表明安全性高。因此，tACS治疗SCA3有效、安全且可行。该研究已在ClinicalTrials.gov（NCT05557786）注册。
Zotero 插件